Remove Events Remove Medical Imaging Remove Radiation Remove Radiation Oncology
article thumbnail

ASRT Foundation Awards International Collaborative Research Grant, Hosts 25th Corporate Roundtable Summit 

Imaging Technology

The research team is using the grant to analyze previous and current advanced practice radiation therapist (APRT) training programs internationally and to identify an evidence-based, best-practice framework for APRT education in the U.S. and Canada. The APRT role practices at an advanced level in radiation therapy. or Canada. “The

article thumbnail

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Imaging Technology

“PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. POSLUMA use contributes to a patient’s overall long-term cumulative radiation exposure.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AHRA Set to Install Board of Directors at Annual Meeting

Imaging Technology

christine.book Mon, 07/10/2023 - 14:05 July 10, 2023 — The Association for Medical Imaging Management will be installing newly-elected officers during its July 12 business meeting during the AHRA 2023 Annual Meeting. The July 9-12 event is being held in Indianapolis, Ind., and commemorating the organization’s 50th year.

article thumbnail

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. The demonstrated performance of PSMA-PET imaging fits an important unmet need, given that conventional imaging techniques are limited in the information they provide. No serious adverse events were observed in the LIGHTHOUSE study.